BTAI Annual CFF
$26.52 M
-$69.72 M-72.44%
31 December 2023
Summary:
As of January 22, 2025, BTAI annual cash flow from financing activities is $26.52 million, with the most recent change of -$69.72 million (-72.44%) on December 31, 2023. During the last 3 years, it has fallen by -$220.84 million (-89.28%). BTAI annual CFF is now -89.28% below its all-time high of $247.36 million, reached on December 31, 2020.BTAI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTAI Quarterly CFF
$454.00 K
-$4.85 M-91.44%
30 September 2024
Summary:
As of January 22, 2025, BTAI quarterly cash flow from financing activities is $454.00 thousand, with the most recent change of -$4.85 million (-91.44%) on September 30, 2024. Over the past year, it has dropped by -$1.67 million (-78.62%). BTAI quarterly CFF is now -99.76% below its all-time high of $187.03 million, reached on September 30, 2020.BTAI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTAI TTM CFF
$34.51 M
+$454.00 K+1.33%
30 September 2024
Summary:
As of January 22, 2025, BTAI TTM cash flow from financing activities is $34.51 million, with the most recent change of +$454.00 thousand (+1.33%) on September 30, 2024. Over the past year, it has increased by +$7.99 million (+30.11%). BTAI TTM CFF is now -88.09% below its all-time high of $289.64 million, reached on June 30, 2021.BTAI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTAI Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -72.4% | -78.6% | +30.1% |
| 3 y3 years | -89.3% | +539.4% | -66.4% |
| 5 y5 years | -52.2% | -97.5% | +93.5% |
BTAI Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -74.1% | at low | -99.3% | -71.3% | +41.1% | |
| 5 y | 5-year | -89.3% | +48.7% | -99.8% | -88.1% | +93.5% | |
| alltime | all time | -89.3% | +1943.3% | -99.8% | +674.7% | -88.1% | >+9999.0% |
BioXcel Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $454.00 K(-91.4%) | $34.51 M(+1.3%) |
| June 2024 | - | $5.30 M(-80.1%) | $34.05 M(+17.4%) |
| Mar 2024 | - | $26.63 M(+1154.2%) | $29.00 M(+9.3%) |
| Dec 2023 | $26.52 M(-72.4%) | $2.12 M(>+9900.0%) | $26.52 M(+8.5%) |
| Sept 2023 | - | $0.00(-100.0%) | $24.45 M(-55.1%) |
| June 2023 | - | $250.00 K(-99.0%) | $54.50 M(-54.7%) |
| Mar 2023 | - | $24.15 M(>+9900.0%) | $120.39 M(+25.1%) |
| Dec 2022 | $96.24 M(-6.1%) | $50.00 K(-99.8%) | $96.24 M(+0.1%) |
| Sept 2022 | - | $30.05 M(-54.6%) | $96.19 M(+45.3%) |
| June 2022 | - | $66.14 M(>+9900.0%) | $66.21 M(-34.8%) |
| Mar 2022 | - | $0.00(0.0%) | $101.59 M(-0.8%) |
| Dec 2021 | $102.45 M(-58.6%) | $0.00(-100.0%) | $102.45 M(-0.2%) |
| Sept 2021 | - | $71.00 K(-99.9%) | $102.68 M(-64.5%) |
| June 2021 | - | $101.52 M(>+9900.0%) | $289.64 M(+53.7%) |
| Mar 2021 | - | $852.00 K(+265.7%) | $188.38 M(-23.8%) |
| Dec 2020 | $247.36 M | $233.00 K(-99.9%) | $247.36 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $187.03 M(>+9900.0%) | $247.22 M(+216.9%) |
| June 2020 | - | $271.00 K(-99.5%) | $78.01 M(+0.5%) |
| Mar 2020 | - | $59.83 M(>+9900.0%) | $77.66 M(+335.5%) |
| Dec 2019 | $17.83 M(-67.9%) | $95.00 K(-99.5%) | $17.83 M(+0.9%) |
| Sept 2019 | - | $17.82 M(<-9900.0%) | $17.68 M(<-9900.0%) |
| June 2019 | - | -$79.00 K(-8000.0%) | -$115.00 K(+85.5%) |
| Mar 2019 | - | $1000.00(-101.7%) | -$62.00 K(-100.1%) |
| Dec 2018 | $55.53 M(+1701.1%) | -$58.00 K(-376.2%) | $55.53 M(-2.3%) |
| Sept 2018 | - | $21.00 K(-180.8%) | $56.82 M(-1.3%) |
| June 2018 | - | -$26.00 K(-100.0%) | $57.59 M(-1.1%) |
| Mar 2018 | - | $55.59 M(+4415.8%) | $58.24 M(+1789.1%) |
| Dec 2017 | $3.08 M(+137.5%) | $1.23 M(+55.6%) | $3.08 M(+66.5%) |
| Sept 2017 | - | $791.00 K(+25.6%) | $1.85 M(+74.6%) |
| June 2017 | - | $630.00 K(+46.2%) | $1.06 M(+146.2%) |
| Mar 2017 | - | $431.00 K | $431.00 K |
| Dec 2016 | $1.30 M | - | - |
FAQ
- What is BioXcel Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual CFF year-on-year change?
- What is BioXcel Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly CFF year-on-year change?
- What is BioXcel Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM CFF year-on-year change?
What is BioXcel Therapeutics annual cash flow from financing activities?
The current annual CFF of BTAI is $26.52 M
What is the all time high annual CFF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual cash flow from financing activities is $247.36 M
What is BioXcel Therapeutics annual CFF year-on-year change?
Over the past year, BTAI annual cash flow from financing activities has changed by -$69.72 M (-72.44%)
What is BioXcel Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BTAI is $454.00 K
What is the all time high quarterly CFF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly cash flow from financing activities is $187.03 M
What is BioXcel Therapeutics quarterly CFF year-on-year change?
Over the past year, BTAI quarterly cash flow from financing activities has changed by -$1.67 M (-78.62%)
What is BioXcel Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BTAI is $34.51 M
What is the all time high TTM CFF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM cash flow from financing activities is $289.64 M
What is BioXcel Therapeutics TTM CFF year-on-year change?
Over the past year, BTAI TTM cash flow from financing activities has changed by +$7.99 M (+30.11%)